AI-generated analysis. Always verify with the original filing.
BD furnished recast historical financial information to reflect its Biosciences and Diagnostic Solutions business as discontinued operations following the February 9, 2026 spin-off and combination with Waters Corporation.
Event Type
Disclosure
Mandatory
Variant
8-K
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. As previously disclosed, on February 9, 2026, Becton, Dickinson and Company (“BD”) completed the spin-off of its
FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99.1 BD Unaudited Recast Financial Information, which is furnished pursuant to Item 2.02. Exhibit 104 Cover Page Inte
| Metric | Value | Basis |
|---|---|---|
| Revenues | $4.5K | |
| Operating Income | $468.00 | GAAP |
| Operating Income | $978.00 | Non-GAAP |
| Net Income from Continuing Operations | $311.00 | GAAP |
| Net Income from Continuing Operations | $716.00 | Non-GAAP |
| Diluted Earnings per Share from Continuing Operations | $1.09 | GAAP |
| Diluted Earnings per Share from Continuing Operations | $2.50 | Non-GAAP |
| Net Income from Discontinued Operations | $71.00 | GAAP |